Double -dose of vitamin D for premature, very low birth infants can safely give their tiny bones a great advantage, providing hope for a stronger start to life.
Study: Effects of completing Vitamin D high dose on bone density at very low birth weight premature infants. Credit Picture: RMC42/Shutterstock.com
A study at Borders in endocrinology Investigated the safety and effectiveness of high doses of vitamin D completion in premature infants of very low birth weight (VLBW). The researchers emphasized that daily completion of 800 IU Vitamin D improves bones in premature infants VLBW.
The effect of vitamin D deficiency in infants
Early VLBW infants usually exhibit vitamin D deficiency due to limited UV exposure, reduced transplantation, challenges in achieving adequate intestinal diet and low -fat mass for storage for vitamin D.
Vitamin D is essential for the overall growth of growth and bone density (BMD) in infants. Previous studies have shown that low BMD in premature infants increases the risk of various skeletal complications, such as premature ripening (OOP) and Rickets.
Vitamin D enhances calcium absorption and phosphate with co-converters of co-converters (NAPI-IIB) and Vanilloid 6 transitional receptor (TRPV6) into enterocytes. Experimental research has shown that activated vitamin D is associated with the Vitamin D (VDR) receptor in osteoblasts, activating the expression of Rankl (Kappa-B nuclear receptor activator), a critical factor of rejuvenation and bone removal factor. In addition, Vitamin D regulates osteocalcin and alkaline phosphatase (ALP), essential ingredients for bones caused by osteoblasts.
Skeletal complications in infants are usually diagnosed using clinical evaluations, biochemical tests and radiological imaging. For example, biochemical tests detect organic markers such as phosphate, ALP, serum calcium and 25-hydroxychbendamin D (25 (oh) D), indicating skeletal complications. X -rays and the absorption of X -energy X -ray (DEXA) are standard radiological methods used to assess bone health.
Previous studies have pointed out the possibility that increased intake of vitamin D can improve bone mineralization and reduce the risk of oop in premature infants. According to European guidelines, 800-1,000 IU/Vitamin D day is more effective, while the US is 400 IU/day for an effective result. The difference in European and US guidelines regarding the dosage of vitamin D creates confusion about its most effective dose and security profile.
For the study
The current retrospective cocktail study compared the efficacy of daily doses of vitamin D of 800 and 400 IU in the improvement of BMD, as measured by Dexa, in VLBW infants. A total of 215 VLBW infants, weighing less than 1500 grams at birth, were examined. All infants hired in this study required Nicu care at Hanyang Seoul University Hospital between January 2011 and December 2022.
The infants selected for this study were divided into two groups. One team received 400 IU/day (n = 70, period 1: January 2011 -October 2015) and the other 800 IU/Vitamin D day (n = 145, period 2: November 2015 -December 2022). Wet cholekaliferol was administered via nasogastric or orogastric on the day 14 of life if the intestinal power was tolerated. This treatment continued until 36 weeks after age menstruation (PMA). As soon as the infant achieved 100 ml/kg/day of intestinal power, they received a maximum total daily vitamin D 900 IU/day by completing and nutrition.
Study findings
The basic features of the 400 IU/DAY and 800 IU/Day teams vary significantly. For example, the 800 IU/Day group had a significantly higher mother age, birth height, birth weight, APGAR scores at 1 and 5 minutes, caesarean section days and days of total parenteral diet (TPN). In contrast, candidates for 400 IU/Day Groups showed a higher postnatal use of corticosteroids and a higher incidence of necrotic enterocolitis (NEC). An acceptable variable balance was estimated between the groups by acquiring standard media (SMD) less than 0.2, except for TPN days.
High -dose treatment of vitamin D has presented consistent standards of bone inorganization in different skeletal positions. Dexa showed significantly higher BMADs of the entire body with 800 IU after IPTW, significant spine profits and left femoral and a positive (non -significant) right thigh voltage. The significant left -wing results of the thigh could be partially attributed to the volatility of placement or measurement in very small premature infants.
Serum 25 (OH) D was only attended by the 800 IU group. No clinical toxicity was observed and the dosage stopped per protocol when levels exceeded 80 ng/ml. Bone density analyzes have revealed a significantly higher BMAD of the entire body in the 800 IU/day from the 400 IU/day group, even after the reverse probability of adjusting the treatment weighing (IPTW).
Radiology depiction using Dexa showed a consistent positive effect of completing vitamin D higher dose on skeletal disorganization, with significant effects on the spine and a left femur and a positive tendency on the right femur.
A biochemical safety assessment based on serum levels 25 (OH) D did not reveal clinical toxicity symptoms. This finding underlined the security of an 800 IU/day in the VLBW population. Bone density analysis revealed that good BMAD infants had a significantly higher bone (BMC) and BMD content compared to other groups. The highest complement of vitamin D and greater pregnancy maturity are vital to improving bones in infants in VLBW infants.
Conclusions
The current study emphasized that, compared to the standard 400 IU dose of vitamin D, a higher dosage of 800 IU, which began in 14 days of life, could significantly increase bones in premature infants with VLBW. The authors mentioned the potential benefits of higher intake of vitamin D in vulnerable infants.
In the future, a similar study using a different population of study from different geographical locations, nationalities, genetic factors and maternal conditions are essential for the validation of the findings of the current study. In addition, standard reference values for the interpretation of Dexa in premature populations, along with other validated methods, must be developed.
